Research Article
Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality
Table 1
Demographic, biochemical, and dialysis-related data for controls and end-stage renal disease patients.
| | Controls () | ESRD patients () | |
| | Gender, (%) | | | | | Male | 8 (36.4) | 134 (54.5) | 0.121 | | Female | 14 (63.6) | 112 (45.5) | | Age (years) | 56.9 [52.3–59.8] | 71.0 [59.7–79.5] | <0.001 | | BMI (kg/m2) | | | 0.215 | | Aetiology of CKD, (%) | | | | | Diabetic nephropathy | — | 87 (35.4) | — | | Hypertensive nephrosclerosis | 34 (13.8) | | Polycystic kidney disease | 17 (6.9) | | Chronic glomerulonephritis | 18 (7.3) | | Other or undetermined | 90 (36.6) | | Dialysis vintage (years) | | 3.87 [1.79–7.48] | | | Dialysis therapy, (%) | | | | | Haemodialysis | — | 30 (12.2) | — | | Online haemodiafiltration | 216 (87.8) | | Vascular access, (%) | | | | | Arteriovenous fistula | — | 199 (80.9) | — | | Arteriovenous graft | 12 (4.9) | | Central venous catheter | 35 (14.2) | | Biochemical and dialysis markers | | | | | Sodium (mEq/L) | — | 137 [135-139] | — | | Potassium (mEq/L) | | | Phosphorus (mg/dL) | 4.14 [3.31–4.99] | | Calcium (mg/dL) | | | Calcium phosphorus product | 36.74 [29.75–44.96] | | Albumin (g/dL) | 3.8 [3.6–4.1] | | URR (%) | 79.0 [75.8–83.0] | | | | | Ultrafiltration volume (L) | 2.3 [1.7–2.9] |
|
|
Data are presented as or as median (interquartile range). ESRD: end-stage renal disease; BMI: body mass index; URR: urea reduction ratio. |
